Bromocriptin Mesylate Tablets IP 2.5 mg Manufacturer

Bromocriptin Mesylate Tablets IP 2.5 mg Manufacturer in India – Healthy Life Pharma Pvt. Ltd.

Bromocriptin Mesylate Tablets IP 2.5 mg Manufacturer product packaging

Bromocriptin Mesylate Tablets IP 2.5 mg | Manufacturer

Product image for Bromocriptin Mesylate Tablets IP 2.5 mg Manufacturer; contract manufacturing, oem & quality control.

Product Information

Generic NameBromocriptin Mesylate
ManufacturerHealthy Life Pharma Pvt. Ltd.
HSN Code30049099
PharmacopoeiaIP
Product TypeTablet
CategoryAntiparkinsonian drugs
SubcategoryAntiparkinsonian drugs
Active IngredientBromocriptin Mesylate
Strength2.5 mg
Dosage FormTablet
Pack Size10 x 10 Tablets / Box (Alu-Alu / Blister)
Route of AdministrationOral
Prescription RequiredYes
Therapeutic CategoryAntiparkinsonian drugs

Medicine Details & Safety

Short DescriptionHealthy Life Pharma invites contract and third-party manufacturing enquiries for Bromocriptin Mesylate Tablets IP 2.5 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements.
Approved Uses / Indications1. Management of generalized tonic-clonic, focal, and absence epileptic seizures. 2. Adjunctive treatment in trigeminal neuralgia, neuropathic pain, and mood stabilization.
Full Description

Healthy Life Pharma invites contract and third-party manufacturing enquiries for Bromocriptin Mesylate Tablets IP 2.5 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements.

Product technical specifications

Generic nameBromocriptin Mesylate
CompositionBromocriptin Mesylate
Strength2.5 mg
CategoryAntiparkinsonian drugs
PharmacopoeiaIP
Dosage formTablet

Product technical specifications

Generic nameAcarbose
CompositionAcarbose
Strength25 mg
CategoryAntidiabetic Drugs
PharmacopoeiaUSP / IP
Dosage formTablet

Manufacturing capabilities and infrastructure

For Bromocriptin Mesylate Tablets IP 2.5 mg, assess the approved formulation process, equipment suitability, batch scale and in-process controls for the Tablet presentation. Confirm environmental requirements and validated process before production.

Quality control and assurance

Request the approved finished-product specification for Bromocriptin Mesylate Tablets IP 2.5 mg, including applicable identity, assay, uniformity and performance tests for the Tablet presentation. Confirm analytical methods, acceptance criteria and batch release documentation, including COA availability.

Primary and secondary packaging

The catalogue pack for Bromocriptin Mesylate Tablets IP 2.5 mg is 10 x 10 Tablets / Box (Alu-Alu / Blister). Confirm primary packaging compatibility, stability evidence, artwork, batch coding and leaflet requirements against the approved specification.

Contract manufacturing and private label

Submit the target market, strength, pharmacopoeial specification, forecast volume and brand artwork. Agree feasibility, batch size, quality agreement, production schedule and release criteria before execution.
Dosage InstructionsAdminister orally at regular scheduled intervals daily. Swallow whole with water; maintain consistent dosing to achieve stable therapeutic anticonvulsant plasma concentrations.
Side EffectsCommon: Drowsiness, fatigue, ataxia, dizziness, diplopia, nausea. Uncommon: Tremor, cognitive slowing, skin rash, mild transaminase elevation. Rare: Stevens-Johnson syndrome, hepatotoxicity, pancreatitis, aplastic anemia.
Warnings and PrecautionsAbrupt Discontinuation: Never stop abruptly; gradual withdrawal over weeks is required to avoid precipitating status epilepticus. Suicidal Ideation: Monitor closely for emergence of depressive mood changes or suicidal thoughts. Hepatic & Hematologic Testing: Regular blood counts and liver enzymes are recommended.
Contraindications1. Known hypersensitivity to Bromocriptin Mesylate or related anticonvulsant chemical structures.
2. Acute intermittent porphyria or atrioventricular conduction block.
3. Severe hepatic impairment or preexisting bone marrow depression.
Drug Interactions1. Other Antiepileptics (Phenytoin, Carbamazepine, Valproate): Mutual metabolic induction or inhibition requiring serum monitoring.
2. Oral Contraceptives: Enzyme-inducing anticonvulsants decrease contraceptive hormone efficacy.
3. CNS Depressants & Alcohol: Marked intensification of central nervous system depression.

Frequently Asked Questions

QuestionAnswer
Can I request third-party manufacturing for Bromocriptin Mesylate Tablets IP 2.5 mg?Submit your brand, quantity and packaging requirements for manufacturing feasibility review.
Which pharmacopoeial standard applies for Bromocriptin Mesylate Tablets IP 2.5 mg?The source specification is IP; confirm the required standard before contracting.
What quality tests are applicable for Bromocriptin Mesylate Tablets IP 2.5 mg?Request the approved finished-product specification and batch testing plan.
Can packaging be customized for Bromocriptin Mesylate Tablets IP 2.5 mg?Submit artwork and pack requirements for technical and regulatory review.
How do I request a manufacturing quotation for Bromocriptin Mesylate Tablets IP 2.5 mg?Provide forecast volume, target market, strength and packaging requirements.

Product Tags

Bromocriptin Mesylate Tablets IP 2.5 mg ManufacturerBromocriptin Mesylate 2.5 mgContract ManufacturingOEM & Quality ControlHealthy Life Pharma Pvt. Ltd.

Product Hashtags

#Bromocriptin#Manufacturer#PharmaB2B

Related Products

Latest Posts